uk 68798 has been researched along with verapamil in 39 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (7.69) | 18.2507 |
2000's | 18 (46.15) | 29.6817 |
2010's | 16 (41.03) | 24.3611 |
2020's | 2 (5.13) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
Keserü, GM | 1 |
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Jia, L; Sun, H | 1 |
Caron, G; Ermondi, G; Visentin, S | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
De Clerck, F; Lu, HR; Remeysen, P | 1 |
Duff, HJ; Exner, DV; Feng, ZP; Geonzon, R; Wang, L; Woodman, RC | 1 |
Gong, Q; January, CT; Makielski, JC; Zhang, S; Zhou, Z | 1 |
Cheng, SL; Johnson, BF; Venitz, J | 1 |
Dai, DZ; Kong, RZ; Li, HT; Wang, YQ | 1 |
Khan, IA | 2 |
Andreas, JO; Hauser, R; Jahnel, U; Linz, K; Schneider, J | 1 |
Hamlin, RL; Keene, BW; Kijtawornrat, A; Nishijima, Y; Roche, BM | 1 |
Hreiche, R; Morissette, P; Turgeon, J; Zakrzewski-Jakubiak, H | 1 |
Du, JR; Li, ML; Yang, Y; Zeng, XR | 1 |
Antoons, G; Attevelt, NJ; Beekman, JD; Belardinelli, L; Gomez, AM; Houtman, MJ; Neco, P; Oosterhoff, P; Oros, A; Rajamani, S; Richard, S; van der Heyden, MA; Ver Donck, L; Vos, MA | 1 |
Florian, J; Galeotti, L; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Sanabria, C; Stockbridge, N; Strauss, DG; Sørensen, JS; Ugander, M; Vicente, J; Waite-Labott, K | 1 |
Haigney, MC | 1 |
Crumb, WJ; Johannesen, L; Mason, JW; Pueyo, E; Stockbridge, N; Strauss, DG; Vicente, J | 1 |
Brown, AM; Bruening-Wright, A; Dittrich, HC; Hawryluk, P; Kramer, J; Obejero-Paz, CA; Tatalovic, M | 1 |
Hosseini, M; Johannesen, L; Mason, JW; Pueyo, E; Sager, PT; Strauss, DG; Vicente, J | 1 |
Árpádffy-Lovas, T; Gazdag, P; Geramipour, A; Jost, N; Kohajda, Z; Orvos, P; Szlovák, J; Tálosi, L; Tóth, D; Varró, A; Virág, L | 1 |
Bergau, D; Bystricky, W; Carter, D; Gintant, G; Kamradt, K; Maier, C; Welsh, P | 1 |
Bai, S; Cao, H; Chen, K; Dong, H; Ma, Y; Pei, J; Tian, L; Zhao, Y | 1 |
3 review(s) available for uk 68798 and verapamil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Dogs; Electric Countershock; Heart Atria; Humans; Myocardial Contraction; Myocardial Stunning; Phenethylamines; Regional Blood Flow; Sotalol; Sulfonamides; Ultrasonography; Verapamil | 2002 |
Atrial stunning: basics and clinical considerations.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Atrial Function, Left; Atrial Function, Right; Catheter Ablation; Electric Countershock; Humans; Isoproterenol; Myocardial Stunning; Phenethylamines; Sotalol; Sulfonamides; Thromboembolism; Time Factors; Verapamil | 2003 |
5 trial(s) available for uk 68798 and verapamil
Article | Year |
---|---|
Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic.
Topics: Adult; Anti-Arrhythmia Agents; Area Under Curve; Calcium Channel Blockers; Drug Interactions; Humans; Kidney; Liver; Male; Metabolic Clearance Rate; Phenethylamines; Potassium Channel Blockers; Sulfonamides; Verapamil | 2001 |
Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.
Topics: Acetanilides; Calcium Channel Blockers; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart Rate; Humans; Phenethylamines; Piperazines; Potassium Channel Blockers; Prospective Studies; Quinidine; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil | 2014 |
Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Topics: Adult; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Heart; Humans; Long QT Syndrome; Male; Phenethylamines; Quinidine; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil | 2015 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Heart; Heart Rate; Humans; Lidocaine; Long QT Syndrome; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Sodium; Sodium Channel Blockers; Sulfonamides; Torsades de Pointes; Verapamil | 2016 |
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization.
Topics: Action Potentials; Adult; Databases, Factual; Double-Blind Method; Electrocardiography; Female; Heart; Humans; Lidocaine; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil; Young Adult | 2019 |
31 other study(ies) available for uk 68798 and verapamil
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disease Models, Animal; Electric Stimulation; Electrocardiography; Encainide; Ethanolamines; Guinea Pigs; Heart; Heart Conduction System; Injections, Intravenous; Male; Metoprolol; Nebivolol; Phenethylamines; Piperidines; Sotalol; Sulfonamides; Ventricular Fibrillation; Verapamil | 1995 |
A high affinity binding site for [3H]-Dofetilide on human leukocytes.
Topics: Animals; Anti-Arrhythmia Agents; Binding Sites; Charybdotoxin; Guinea Pigs; Humans; Kinetics; Leukocytes; Neuropeptides; Neutrophils; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Shaw Potassium Channels; Sulfonamides; Tetraethylammonium; Verapamil | 1998 |
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
Topics: Anti-Arrhythmia Agents; Calcium Channel Blockers; Cation Transport Proteins; Cell Line; Diltiazem; DNA-Binding Proteins; Electric Conductivity; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrogen-Ion Concentration; Intracellular Membranes; Mutation; Nifedipine; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Trans-Activators; Transcriptional Regulator ERG; Verapamil | 1999 |
Frequency dependent prolongation of effective refractory period by a complex class III antiarrhythmic agent CPU-86017.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzeneacetamides; Berberine; Calcium Channel Blockers; Female; Guinea Pigs; Heart Atria; In Vitro Techniques; Male; Papillary Muscles; Phenethylamines; Piperidines; Potassium Channel Blockers; Refractory Period, Electrophysiological; Sulfonamides; Verapamil | 2001 |
Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Topics: Animals; Calcium Channel Blockers; Dogs; Electrocardiography; Ether-A-Go-Go Potassium Channels; Humans; Male; Phenethylamines; Potassium Channels; Sotalol; Sulfonamides; Torsades de Pointes; Verapamil | 2005 |
Use of a failing rabbit heart as a model to predict torsadogenicity.
Topics: Amiodarone; Animals; Cardiac Output, Low; Cisapride; Dose-Response Relationship, Drug; Electrocardiography; Models, Animal; Phenethylamines; Quaternary Ammonium Compounds; Quinidine; Rabbits; Sulfonamides; Torsades de Pointes; Verapamil | 2006 |
Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Delayed Rectifier Potassium Channels; Domperidone; Female; Guinea Pigs; Heart Conduction System; Indapamide; Long QT Syndrome; Male; Phenethylamines; Potassium Channel Blockers; Sex Factors; Sexual Development; Sulfonamides; Time Factors; Verapamil | 2009 |
[Effects of combined use of dofetilide and verapamil on the action potential of papillary muscles in guinea pigs].
Topics: Action Potentials; Animals; Calcium Channel Blockers; Drug Synergism; Female; Guinea Pigs; In Vitro Techniques; Male; Microelectrodes; Papillary Muscles; Phenethylamines; Potassium Channel Blockers; Sulfonamides; Verapamil | 2009 |
Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cell Line; Dogs; Flunarizine; Humans; Lidocaine; Mice; Myocytes, Cardiac; Phenethylamines; Sulfonamides; Torsades de Pointes; Verapamil | 2010 |
Looking for virtuous promiscuity: electrocardiographic evidence of multichannel drug block.
Topics: Acetanilides; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Phenethylamines; Piperazines; Potassium Channel Blockers; Quinidine; Ranolazine; Sulfonamides; Verapamil | 2014 |
Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.
Topics: Action Potentials; Animals; Bepridil; CHO Cells; Computer Simulation; Cricetulus; Ether-A-Go-Go Potassium Channels; Heart; HEK293 Cells; Humans; Inhibitory Concentration 50; Ion Channels; Membrane Potentials; Models, Biological; Myocardium; Myocytes, Cardiac; Patch-Clamp Techniques; Phenethylamines; Piperazines; Sulfonamides; Verapamil | 2015 |
Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Female; Heart Ventricles; Humans; Ion Channels; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Rabbits; Sotalol; Sulfonamides; Terfenadine; Tissue Donors; Verapamil | 2019 |
Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cations, Divalent; Cell Differentiation; Humans; Induced Pluripotent Stem Cells; Ion Transport; Microelectrodes; Models, Biological; Myocardial Contraction; Myocytes, Cardiac; Nifedipine; Patch-Clamp Techniques; Phenethylamines; Primary Cell Culture; Quinidine; Sotalol; Sulfonamides; Tetrodotoxin; Verapamil | 2021 |